Celitrion, Inc.

← The SEC Ephemeris: the whole map

Celitrion, Inc. CT-P17

In the graph: all 2 documents (5 pages).

Application: BLA 761219
Ticker: Celitrion, Inc.
Product: CT-P17
Disease area: Not yet classified
Response path: Not yet classified
Complete Response Letters: November 23, 2022 · November 24, 2021

From FDA letters and SEC filings. Not investment or medical advice.

Not yet classified

B. Braun Medical, Inc. Acetaminophen
Bausch Health Ireland Limited fluorescein sodium
Baxter Healthcare Corporation DAPZURA RT
Bayer HealthCare LLC Naproxen sodium
Belcher Pharmaceuticals, LLC. Ablysinol
BendaRx USA Corporation bendamustine
Bio-Thera Solutions Ltd. BAT1706
Biogen, Inc.
Biohaven Therapeutics, Ltd. troriluzole
Bioprojet Pharma Wakix
Bioverativ USA, Inc. sutimlimab
Botanix SB Inc. sofpironium bromide
Braeburn Inc. BRIXADI
Braeburn Pharmaceuticals Inc. BRIXADI
Braintree Laboratories, Inc. Suflave
Bridge Regulatory Affairs, LLC octreotide hydrochloride extended- release
Bristol-Myers Squibb dapagliflozin
Cadence Pharmaceuticals Ofirmev
Camargo Pharmaceutical Services Mycapssa
Capricor, Inc. deramiocel
Celitrion, Inc. CT-P17
CellTrans Inc. Donislecel manufactured at your Chicago
CELLTRION, Inc. Steqeyma
Checkpoint Therapeutics, Incorporated cosibelimab
Chelsea Therapeutics, Inc. NORTHERA
Chemo Research, S.L. dienogest
Chiesi USA, Inc. PRX-102
Cingulate Therapeutics, LLC dexmethylphenidate hydrochloride
Cipla USA, Inc.
Citius Pharmaceuticals, Inc. Lymphir
Clarus Therapeutics, Inc. testosterone undecanoate
CLASS 2 RESUBMISSION Romidepsin
Clearside Biomedical, Inc. XIPERE
CMP Development LLC sildenafil
Coherus BioSciences, Inc. toripalimab-tpzi
Conjupro Biotherapeutics Inc. irinotecan liposome
CooperSurgical, Inc. Paragard
Corium, Inc. ADLARITY
CorMedix Inc. taurolidine
CSL Behring LLC CSL312

All 283 on the full map →

Group by

Build queue · replay at pipeline speed